Synthesis of N-heterocyclic nitrenium (NHN) ions and related donor systems: Coordination with d10-metal ions
作者:Sangeeta Yadav、Rajesh Deka、Saravanan Raju、Harkesh B. Singh
DOI:10.1016/j.ica.2019.01.024
日期:2019.3
three new NNN- and CNC type N-heterocyclic nitrenium (NHN) ion based pincer ligands is reported from 1,3-di-(2′-bromoethyl)-triazolium bromide (5). The reaction of 5 with ammonium hexafluorophosphate followed by two equivalent of pyrrolidine/diethylamine afforded NHN ions (10a and 10b). The reaction of 5 with N-butylbenzimidazole (6) afforded nitreniumion 7, where the chelating arms have benzimidazole
Studies on Potential Antiviral Compounds, XXII Synthesis and in Vitro Antiviral Activity of 1-(Hydroxyalkyl)-1H-benzimidazoles
作者:Laura Garuti、Anna Ferranti、Giuseppe Giovanninetti、Giancarlo Scapini、Loredano Franchi、Maria P. Landini
DOI:10.1002/ardp.19823151206
日期:——
A series of 1‐(hydroxyalkyl)‐1H‐benzimidazoles has been prepared and screened in vitro for activity against herpes simplex virus, type 2 (DNA) and poliovirus type 1 (RNA). 5,6‐Dichloro‐1‐[2‐(2‐hydroxyethoxy)ethyl]‐1H‐benzimidazole (9, Table 1) was the most significant compound.
investigate of cytotoxic effect and apoptosis mechanism on breastcancercell lines (MCF7), breast adenocarcinoma cell lines (MDA-MB-231), and non-tumorigenic epithelium cell lines (MCF 10A) of new Ag(I)-NHC complexes that derivative from morpholine-linked benzimidazole, were synthesized and antimicrobial activity was determined in our previous study. The cytotoxicity was determined by the MTS method
COMPOUNDS FOR USE IN ELECTROLYTE FOR SOLAR CELL, METHOD FOR PREPARING THE SAME, AND ELECTROLYTE AND SOLAR CELL HAVING THE SAME
申请人:Lee Yu-Hui
公开号:US20130056075A1
公开(公告)日:2013-03-07
Provided is a compound of formula (I):
wherein A is C
2-3
alkylene; m is an integer ranging from 2 to 25; and n is an integer ranging from 3 to 10. An electrolyte for a dye-sensitized solar cell having the compound of formula (I) and/or a compound of formula (II) is further provided for increasing photoelectric conversion efficiency.
Nonpeptide agonists and antagonists of vasopressin receptors
申请人:——
公开号:US20020128208A1
公开(公告)日:2002-09-12
The disclosed invention is a composition agonists and/or antagonists of V
2
, V
1a
or both receptors, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.